Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+0.52%
SPX
+0.53%
IXIC
+0.52%
FTSE
-0.86%
N225
NaN%
AXJO
0.00%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks
Stocks
0.00 (0.00%)
0.000
USD
At close at --,----
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.

Join our newsletter to keep up to date with us!

Overview

Loading chart...

Key Stats

Market Cap
3.77B
Dividend Yield
0.00%
P/E Ratio
-21.95
EPS
-1.00
Revenue
-
Avg. Volume
4.10M
Stocks
Health Care
vktx
Viking Therapeutics
NASDAQ: VKTX
-1.21 (-3.48%)
33.52
USD
At close at Oct 17, 20:39 UTC
Summary
News
Signals
Benchmarks
Financials

About

What does VKTX do?
Viking Therapeutics, based in San Diego, develops therapies for metabolic and endocrine disorders, including VK2809 for NASH, VK0214 for X-ALD, and VK2735 for metabolic issues. The company went public on April 29, 2015, and has 28 employees.
Sector
💻 Health Care
IPO
CEO
Employees
48
Headquarters
California, USA
Website
http://www.vikingtherapeutics.com

Recently from Cashu

publisher logo
Cashu

Viking Therapeutics Stock Sentiment Shifts Amid High Short Interest and Clinical Developments

about 1 month ago
publisher logo
Cashu

Viking Therapeutics Faces Market Skepticism Amid High Short Interest and Clinical Development Challenges

about 1 month ago
publisher logo
Cashu

Viking Therapeutics: Key Clinical Trials and Strategic Partnerships Shape Future Prospects

about 1 month ago